Blueprint Medicines Corporation announced AYVAKIT data showing high, durable response rates and prolonged overall survival (OS) in patients with advanced systemic mastocytosis (Advanced SM),...
Analysis Group, a global leader in health economics and outcomes research (HEOR) and regulatory epidemiology, announced that a study it coauthored helped support Blueprint...
